How do you buy and bill biologics like Xolair without losing money on the drug?

How does buy and bill work, step by step?

Buy and bill means the practice buys the drug, owns it as inventory, administers it, and bills the payer afterwards for both the drug and the administration. The payer reimburses under the medical benefit, not the pharmacy benefit, so the claim carries a HCPCS J code for the product and a CPT code for the injection or infusion. The practice is the one holding the financial risk between purchase and payment.

The buy and bill process in six steps

Every buy and bill process runs the same six steps, and each one has a place where money leaks.

1. Benefits investigation. Confirm the drug is a medical benefit for that plan, confirm the site of care, and confirm the patient’s coinsurance position before you order.
2. Prior authorization. Get it in writing with the approved units, the approved date range and the approved place of service. Medicare fee for service has no prior authorization program covering office administered Part B drugs, but Medicare Advantage plans may apply prior authorization and step therapy to Part B drugs, and commercial plans almost always do.
3. Purchase. Order from your distributor or group purchasing organization at a contracted price, on terms that are usually net 30.
4. Administration and charge capture. Document the dose in milligrams, the National Drug Code, the lot and the exact amount discarded.
5. Claim submission. The drug line carries the J code, the units, the NDC and the waste modifier; the administration line carries the CPT code.
6. Payment posting. Post against the contracted rate, not against whatever the remittance says, and work the variance.

Buy and bill pharmacy rules versus the medical benefit

A buy and bill pharmacy arrangement is not a specialty pharmacy arrangement, and the difference decides who gets paid. Under buy and bill, the practice is the seller of record and bills the drug on the medical claim. Under white bagging, a specialty pharmacy dispenses the patient specific drug under the pharmacy benefit and ships it to you, so you bill only the administration. Under brown bagging, the patient carries it in. Economics, storage duties and liability for a wasted vial all move with that choice.

Because the drug rides on the medical claim, the work sits with the billing team rather than a pharmacy. Our full service medical billing team owns the drug line and the administration line together, and eligibility and prior authorization is where the buy and bill process either holds or breaks.

Why does ASP plus 6% pay less than 6%?

Because two separate mechanics take a cut before the money reaches you. Medicare pays 106 percent of the average sales price for most separately payable Part B drugs under 42 CFR 414.904, but the published rate is historical and the payment itself is reduced. Work the arithmetic and the real figure is closer to ASP plus 4.3 percent, and that is before your own acquisition price enters the picture.

The two-quarter ASP lag

Manufacturers report ASP for a calendar quarter within 30 days of that quarter ending. CMS then publishes a payment limit file that takes effect two quarters after the sales quarter it was calculated from. CMS calls this the two-quarter lag in its own fact sheet on the Part B Drug Payment Limit File. The practical effect: the rate you are paid in October is built on sales made in April through June. If the manufacturer raised its price in August, you pay the new price and you are reimbursed on the old one for two more quarters. For a drug that moves a few percent a quarter, that lag is the whole margin.

Sequestration comes off the whole fee

The 2 percent Medicare sequestration reduction has applied to fee for service claims with dates of service on or after April 1, 2013. It is taken from the calculated payment amount after the allowed amount is set, which means it comes off the entire drug fee rather than off the 6 percent add on. Beneficiary deductible and coinsurance are not reduced. Run it through: on an allowed amount of 106 percent of ASP, Medicare pays 80 percent of that less 2 percent, the patient owes 20 percent of the full allowed amount, and the total that reaches the practice is 104.3 percent of ASP. The 6 percent everyone quotes is, in cash, 4.3 percent, and only if the patient pays.

What does a 300 mg Xolair dose actually net?

On the April 2026 CMS ASP pricing file, J2357 has a payment limit of $41.823 per unit, so a 300 mg dose allows $2,509.38. After sequestration on the Medicare share, the practice collects about $2,469 if the patient pays the full coinsurance. Whether that is a profit depends entirely on the invoice.

The chart shows the erosion on one dose: $2,509 allowed at ASP plus 6 percent, about $2,469 after the 2 percent sequestration, an invoice cost of $2,380, and $89 left on the drug.

Xolair J code units: how J2357 is counted

The Xolair J code is J2357, described as injection, omalizumab, 5 mg. Units are multiples of the descriptor, so you divide the milligram dose by 5. A 150 mg dose is 30 units, 300 mg is 60 units, and 375 mg is 75 units. Every Xolair presentation is a single dose container under the FDA label, which is what pulls the waste modifiers into play. The administration line is CPT 96372 for a subcutaneous injection. Get the unit conversion wrong in either direction and you either give the drug away or invite a post payment audit. Our medical coding team scrubs the unit to milligram relationship on every drug line before submission.

The worked example: 40 patients at Ridgeline Allergy

Take a three provider allergy practice collecting $90,000 a month, with 40 Xolair patients averaging 300 mg every four weeks. That is 40 doses a month, $100,375 in allowed drug charges, and roughly $98,770 collected once sequestration is applied and assuming every patient pays. At an invoice price of $2,380 a dose, the practice spends $95,200 to earn $98,770. Net on the drug: $3,570 a month, or 3.6 percent.

Now change one variable. If five patients a month do not pay their $502 coinsurance, that is $2,510 gone and the margin falls to $1,060. If the manufacturer raises price 3 percent while your reimbursement is still on the old ASP, your cost rises $2,856 a month and you are underwater. One 300 mg syringe drawn for a no show costs $2,380 against a monthly margin of $3,570. The model lives inside a 3 to 4 percent band, which is why the operational detail is the business.

How do you find the drugs you are losing money on?

You compare your landed cost per unit against the current payment limit per unit, drug by drug, every quarter. Most practices never do this, which is how a drug goes underwater and stays there for a year. In our billing reviews, 4 in 10 practices reviewed were underwater on at least one buy and bill drug at the time of the review, and in most cases nobody in the practice knew.

The quarterly underwater check

Build one sheet with a row per J code and six columns: landed cost per billing unit, the current CMS payment limit per unit, your top commercial contract rate per unit, units dispensed last quarter, the gap per unit, and the gap times volume. Refresh it in the first week of January, April, July and October when CMS posts the new ASP pricing file. Any negative gap gets one of four decisions: renegotiate with the distributor or group purchasing organization, move to a biosimilar, accept white bagging for that one drug, or refer the patient out. A biosimilar can be paid its own ASP plus 6 percent of the reference product's ASP in defined circumstances, for as long as five years, which can turn a negative gap positive with no clinical change.

Commercial contracts need the same treatment. Underpayments against contracted rates appeared on 7.8% of paid claims in our audit, and the average underpaid claim was short by $38. That is a nuisance on an office visit. On a drug line priced in thousands, the same percentage error is real money, and it is invisible unless you post to the contract. Denials and AR recovery work starts with that variance report, not with the denial list.

Which billing mistakes cost the most on drug claims?

The expensive mistakes are not clinical. They are unit and code mismatches, authorizations that expired mid course, and waste that was never billed. Across our claim audit, eligibility and coverage errors caused 24% of denials, coding and modifier errors caused 21% of denials, and missing or invalid prior authorization caused 17% of denials; duplicate claims made up 9% of denials and timely filing caused 6% of denials.

Drug claims skew harder toward the first three. Unit and NDC mismatches caused 22% of buy and bill drug denials in our audit, and lapsed biologic re-authorizations caused 31% of GI infusion denials, which is the same failure in a different specialty.

J code billing errors that get drug lines returned

Five j code billing errors account for most returned drug lines: the NDC is missing or does not match the presentation used; the units are entered in vials or milligrams instead of billing units; the authorization on file is for a different J code, dose or place of service; the waste modifier is absent on a single dose container claim; or the drug was given under an authorization that had already lapsed. All five are cheap to catch before submission and expensive afterwards: 19% of denied claims were never reworked or appealed in the practices we reviewed, and appeals filed by our team were overturned 68% of the time.

JW and JZ are a pair

JW reports the amount of a single dose container that was discarded. JZ reports that none was discarded. CMS has required JZ on all claims for drugs from single dose containers with no discarded amount since July 1, 2023, and from October 1, 2023 claims that do not use the modifiers appropriately can be returned as unprocessable. Practices treat JW as the one that matters because it pays, and forget JZ because it does not, which is why JW or JZ drug waste modifiers were missing on 11% of single-dose vial claims in our audit. On a 150 mg vial used for a 100 mg dose, the discarded 50 mg is billable revenue you are entitled to and are probably not claiming.

How much cash do you need before you start?

Enough to cover one full replenishment cycle plus the gap between your distributor terms and your slowest payer. Distributor terms are typically net 30. Payment timing is not.

Against net 30 distributor terms, Medicare pays in about 21 days, commercial plans in about 34 days, and Medicare Advantage plans in about 47 days. A practice running $95,000 a month of drug through a Medicare Advantage heavy panel needs roughly $55,000 of working capital permanently tied up in the gap, on top of the inventory on the shelf.

Break-even volume

The break-even question is simpler than it looks. Buy and bill only beats white bagging when the margin on your monthly volume exceeds the cost of running the program: the storage, the temperature monitoring, the inventory count, the benefits checks and the working capital. Put a number on that overhead, divide by your margin per dose, and you have the monthly dose count you need. At a $90 margin per dose and $2,500 a month of program overhead, that is 28 doses a month. Below it, you are subsidising the payer. Practices that reviewed AR ageing monthly carried 12 fewer days in AR, and every 10 days removed from AR released a median $41,000 in cash for practices in the $500,000 to $3 million range, which is the cheapest source of the working capital this model needs. That is the core of revenue cycle management for any drug heavy practice.

What do you do when a payer mandates white bagging mid-course?

Check the state law first, then the contract, then the clinical risk. Several states restrict payer mandated white bagging. Louisiana Act 50 of 2021 bars an issuer from denying or reducing payment to a participating provider because the drug came from outside the issuer's pharmacy network, and Utah S.B. 193 of 2023 bars an insurer from requiring a clinician administered drug to be dispensed by a pharmacy the insurer selects. If your state has such a law and the plan is not self funded, the mandate may not be enforceable.

White bagging vs buy and bill: what changes for the practice

White bagging removes the acquisition risk and the margin together. You stop carrying inventory, you stop eating expired vials, and you bill the administration code only. In exchange you get patient specific stock that has to be segregated and refrigerated, a shipment that may not arrive before the appointment, and a therapy gap if it does not. For a drug you dispense twice a month, white bagging is usually right. At 40 doses a month, price the decision before you make it.

If you are weighing whether your current team can hold this up, a free billing review will tell you which of your drug lines are underwater before you decide anything.

Buy and bill vs specialty pharmacy: which model keeps more of the drug dollar?

Buy and bill keeps the drug margin and the risk together in the practice. Specialty pharmacy models move both to the pharmacy, leaving the practice with the administration fee and the scheduling problem.

The comparison is not about which model is better in general. It is about which model is better for one drug, at your volume, under your contracts. Practices that pick a vendor on price alone tend to skip this analysis entirely, which is the first thing to ask about when you are comparing medical billing companies.

Allergy and immunology

Xolair, Dupixent, Nucala, Fasenra and Tezspire sit alongside allergen immunotherapy, and the two economics are nothing alike. Immunotherapy is billed on 95165 doses and is a volume business; biologics are a margin business priced in thousands per administration. Watch the dose schedule change that follows a weight or IgE recheck, because a 300 mg patient who moves to 375 mg needs a new authorization and 75 units rather than 60. See our allergy and immunology billing page for the coding detail.

Oncology and infusion

Volume makes the ASP lag brutal and the biosimilar decision valuable. A single oncology drug can account for more revenue than all of a practice's visits combined, so a one percent acquisition change is material. Infusion adds hierarchy rules and time thresholds on top of the drug line. Our infusion billing and infusion revenue cycle management pages cover the administration coding and the acquisition workflow.

Gastroenterology

Infliximab, vedolizumab and ustekinumab are all re-authorized on a schedule, and the schedule is where the money goes. Lapsed biologic re-authorizations caused 31% of GI infusion denials in our audit. Biosimilar infliximab has multiple products with different ASPs, so the underwater check has to run per product, not per molecule.

Behavioral health

Esketamine and long acting injectable antipsychotics are the buy and bill drugs here, and the REMS or observation requirement puts real staff cost on the administration side that the drug margin has to cover. Carve-outs make the benefit investigation harder: the same patient can have the drug on the medical benefit and the visit on a behavioral health carve-out.

Primary care

Most primary care buy and bill is vaccines, Depo-Provera, B12 and the occasional biologic started elsewhere. Margins per unit are small, so the failure mode is different: missing administration codes and unbilled product rather than an underwater drug. The discipline that matters is charge capture, not acquisition. Collecting the patient share on anything expensive is the other half, and patient billing is where a $502 coinsurance either lands or becomes bad debt.